Influence of Hesperidin and Vitamin C on Uric Acid Concentration

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04316390

Acronym

HesperiDrinC

Enrollment

Registered

2020-03-20

Start date

2022-07-15

Completion date

2023-03-30

Last updated

2023-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Higher Uric Acid Concentrations (>5,5 mg/dl), Healthy

Keywords

hesperidin, vitamin C, uric acid concentration

Brief summary

Aim of the study is to investigate the impact of hesperidin and/or vitamin C on elevated uric acid concentrations.

Detailed description

Duration of the study is 9 weeks. 1) a washout week, 2) two intervention weeks, 3) four weeks washout period, 4) two intervention weeks. The study is conducted under free living conditions. During washout weeks consumption of orange juice or citrus fruits or vitamin C containing supplements is restricted. During intervention weeks 200 mL of study drink is consumed daily. And participants are asked to maintain their normal physical activity and habitual diet. Additional citrus or vitamin C containing beverages are not allowed. At the beginning and the end of each intervention phase uric acid, insulin sensitivity, blood pressure, pulse wave velocity and bioavailability of hesperidin are assessed.

Interventions

DIETARY_SUPPLEMENTControl

study drink (two weeks)

DIETARY_SUPPLEMENTHesperidin

study drink + Hesperidin 600 mg (two weeks)

DIETARY_SUPPLEMENTVitamin C

study drink + Vitamin C 250 mg (two weeks)

DIETARY_SUPPLEMENTHesperidin + Vitamin C

study drink + Hesperidin 600 mg + Vitamin C 250 mg (two weeks)

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

20 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* healthy * higher uric acid concentration (≥5.5 mg/dL) * Informed written consent

Exclusion criteria

* pregnancy * fructose intolerance * smoking * gout or medicated hyperuricemia * diabetes mellitus * antidiabetic or cytostatic medication * weight loss (≥5% in the past 3 months) * consumption of vitamin C-containing supplements * parallel participation in a clinical trial * anemia and / or iron deficiency

Design outcomes

Primary

Measure	Time frame	Description
Changes in uric acid serum concentrations	Baseline (pre) and post two weeks of intervention	measured via uric acid serum concentration (mg/dL)

Secondary

Measure	Time frame	Description
changes in uric acid excretion	Baseline (pre) and post two weeks of intervention	measured via uric acid excretion in 24h urine (mg/24h)
changes in pulse wave velocity	Baseline (pre) and post two weeks of intervention	measured via oscillometric method (m/s)
insulin sensitivity	Baseline (pre) intervention periods	measured via minimal model from oral glucose tolerance test data using the particular study drink with added glucose to 75 g Glucose / 200 mL

Other

Measure	Time frame	Description
bioavailability of hesperidin in blood	Baseline (pre) and post two weeks of intervention	detection of hesperidin metabolites measured via chromatography and following mass spectrometry in serum
bioavailability of hesperidin in urine	Baseline (pre) and post two weeks of intervention	detection of hesperidin metabolites measured via chromatography and following mass spectrometry in 24h urine

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026